<div id="readability-page-1"><p><span>Bio-Techne (NASDAQ:TECH - Get Free Report)</span> was downgraded by stock analysts at Leerink Partners from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report issued on Thursday,Zacks.com reports.</p><ul><li>Bio-Techne, J2 Global And InMode Break Out Of Bases, Near Buy Points</li></ul><p>Other analysts have also issued reports about the stock. Deutsche Bank Aktiengesellschaft lowered shares of Bio-Techne from a &#34;buy&#34; rating to a &#34;hold&#34; rating and set a $73.00 price target on the stock. in a research report on Friday. Zacks Research lowered Bio-Techne from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research note on Monday, June 8th. William Blair downgraded shares of Bio-Techne from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a research note on Thursday. Piper Sandler initiated coverage on shares of Bio-Techne in a report on Thursday, June 11th. They issued a &#34;neutral&#34; rating and a $65.00 target price on the stock. Finally, TD Cowen  reaffirmed a &#34;buy&#34; rating on shares of Bio-Techne in a research note on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned  a Buy rating, six have given a Hold rating and one  has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $65.79.</p><p><b>View Our Latest Research Report on TECH</b></p><h2>Bio-Techne Stock Performance</h2><p>Shares of TECH opened at $70.70 on Thursday. The company has a market capitalization of $11.07 billion, a PE ratio of 102.47, a P/E/G ratio of 5.67 and a beta of 1.37. The company has a quick ratio of 3.18, a current ratio of 4.49 and a debt-to-equity ratio of 0.10. The company has a 50-day simple moving average of $52.70 and a 200-day simple moving average of $56.99. Bio-Techne has a 52-week low of $43.19 and a 52-week high of $72.16. </p><p>Bio-Techne (NASDAQ:TECH - Get Free Report) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $0.53 EPS for the quarter, missing analysts' consensus estimates of $0.55 by ($0.02). Bio-Techne had a return on equity of 13.57% and a net margin of 9.05%.The firm had revenue of $311.42 million for the quarter, compared to analysts' expectations of $316.11 million. During the same quarter in the previous year, the firm posted $0.56 earnings per share. The firm's revenue for the quarter was down 1.5% compared to the same quarter last year.  Equities research analysts predict that  Bio-Techne will post 1.66 earnings per share for the current fiscal year. </p><h2>Hedge Funds Weigh In On Bio-Techne</h2><p>Several hedge funds and other institutional investors have recently bought and sold shares of the stock. NewEdge Advisors LLC grew its position in  Bio-Techne by 15,993.8% in the first quarter. NewEdge Advisors LLC now owns 7,725 shares of the biotechnology company's stock valued at $404,000 after acquiring an additional 7,677 shares in the last quarter.  Henshaw Capital LLC increased its stake in  Bio-Techne by 31.2% during the 1st quarter. Henshaw Capital LLC now owns 45,905 shares of the biotechnology company's stock worth $2,399,000 after buying an additional 10,915 shares during the period.  Summitry LLC lifted its holdings in  Bio-Techne by 17.1% in the 1st quarter. Summitry LLC now owns 6,013 shares of the biotechnology company's stock worth $314,000 after buying an additional 879 shares in the last quarter.  Intrinsic Edge Capital Management LLC purchased a new position in  Bio-Techne in the 1st quarter valued at about $5,749,000.  Finally, Edgestream Partners L.P. purchased a new position in  Bio-Techne in the 1st quarter valued at about $292,000. 98.95% of the stock is owned by institutional investors and hedge funds. </p><h2>Key Headlines Impacting Bio-Techne</h2><p>Here are the key news stories impacting Bio-Techne this week:</p><ul>   <li><span>Positive Sentiment: </span>Merck KGaA agreed to buy Bio-Techne for $73 per share in cash, giving shareholders a clear exit value and likely driving the stock toward the deal price. <i></i><span>Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne</span></li>   <li><span>Positive Sentiment: </span>The offer represents a sizable premium to Bio-Techne’s recent share price, which typically boosts takeover-target stocks as investors price in deal completion. <i></i><span>Germany's Merck to buy Bio-Techne for $73 per share</span></li>   <li><span>Neutral Sentiment: </span>Multiple law firms announced shareholder investigations into whether Bio-Techne’s board secured a fair price, which could create legal noise but does not change the announced deal terms. <i></i><span>Shareholder Alert: Ademi LLP investigates whether Bio-Techne Corporation is obtaining a Fair Price for Public Shareholders</span></li>   <li><span>Neutral Sentiment: </span>Reported short-interest data showed no meaningful short position, so the move appears driven more by the takeover announcement than by short covering. <i></i><span>Bio-Techne Surges on $73-Per-Share Cash Takeover Agreement</span></li> </ul><h2>About Bio-Techne</h2> (Get Free Report)<p>Bio-Techne Corporation <span>NASDAQ: TECH<span></span></span> is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&amp;D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.  </p><p>Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Bio-Techne</li><li>BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone</li><li>MDA Space Targets US Defense Market With $620M Acquisition</li><li>Carnival's Second Quarter: Is the Stock Still Complicated?</li><li>Domino's Stock Slides to 52-Week Low as Investors Digest CEO Change</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVDSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVDSA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Bio-Techne Right Now?</h2><p>Before you consider Bio-Techne, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Techne wasn't on the list.</p><p>While Bio-Techne currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

TECH

<p>Leerink Partners downgraded Bio-Techne (NASDAQ:TECH) from 'strong-buy' to 'hold'. Other analysts also adjusted ratings, with Deutsche Bank and William Blair moving to 'hold', Zacks to 'strong sell', and Piper Sandler initiating with 'neutral'. TD Cowen reaffirmed a 'buy'. The stock is trading near $70.70, with a consensus target of $65.79. Merck KGaA agreed to acquire Bio-Techne for $73 per share in cash.</p>

Bio-Techne (NASDAQ:TECH) Cut to "Hold" at Leerink Partners